Novavax, Inc. (NASDAQ:NVAX) Position Increased by Victory Capital Management Inc.

Victory Capital Management Inc. raised its holdings in shares of Novavax, Inc. (NASDAQ:NVAX) by 12.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 19,292 shares of the biopharmaceutical company’s stock after purchasing an additional 2,072 shares during the period. Victory Capital Management Inc.’s holdings in Novavax were worth $244,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD grew its position in shares of Novavax by 17.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 56,065 shares of the biopharmaceutical company’s stock worth $269,000 after acquiring an additional 8,128 shares during the last quarter. California State Teachers Retirement System grew its position in shares of Novavax by 11.3% during the first quarter. California State Teachers Retirement System now owns 107,511 shares of the biopharmaceutical company’s stock worth $514,000 after acquiring an additional 10,949 shares during the last quarter. Tidal Investments LLC bought a new position in shares of Novavax during the first quarter worth about $172,000. Swedbank AB bought a new position in shares of Novavax during the first quarter worth about $26,000. Finally, Baader Bank Aktiengesellschaft bought a new position in shares of Novavax during the second quarter worth about $216,000. Institutional investors own 53.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on NVAX. B. Riley reiterated a “buy” rating and issued a $26.00 target price (up previously from $23.00) on shares of Novavax in a research report on Thursday, October 10th. JPMorgan Chase & Co. increased their target price on shares of Novavax from $8.00 to $9.00 and gave the company an “underweight” rating in a research report on Monday, August 12th. HC Wainwright reiterated a “buy” rating and issued a $19.00 target price on shares of Novavax in a research report on Tuesday, November 12th. Finally, Jefferies Financial Group cut their price target on shares of Novavax from $31.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, October 16th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $17.83.

Novavax Stock Up 1.2 %

Shares of NVAX stock opened at $8.72 on Friday. Novavax, Inc. has a 12 month low of $3.53 and a 12 month high of $23.86. The business’s 50 day moving average is $10.40 and its two-hundred day moving average is $12.57. The company has a market cap of $1.40 billion, a PE ratio of -3.86 and a beta of 2.10.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.07. The company had revenue of $84.51 million for the quarter, compared to analyst estimates of $65.80 million. During the same quarter last year, the business earned ($1.26) EPS. The company’s revenue for the quarter was down 54.8% on a year-over-year basis. As a group, equities analysts expect that Novavax, Inc. will post -1.4 EPS for the current fiscal year.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.